Human Osteopontin(OPN) enzyme-linked immunoassay kit
Specification | 96 Test |
---|---|
Sensitivity | 0.04 ng/ml (50 μl);0.12 ng/ml (10 μl) |
Standard Curve Range | 0.31~20 ng/ml |
Standard Curve Gradient | 7 Points |
Number of Incubations | 2 |
Sample Volume | 50 μl/10 μl |
Type | Ready-to-Use |
Operation Duration | 120min |
ng/ml | O.D. | Average | Corrected | |
---|---|---|---|---|
0.00 | 0.0165 | 0.0176 | 0.0171 | |
0.31 | 0.0363 | 0.0396 | 0.0380 | 0.0209 |
0.63 | 0.0749 | 0.0860 | 0.0805 | 0.0634 |
1.25 | 0.1778 | 0.1955 | 0.1867 | 0.1696 |
2.50 | 0.4225 | 0.4620 | 0.4423 | 0.4252 |
5.00 | 1.0110 | 1.0540 | 1.0325 | 1.0155 |
10.00 | 2.0350 | 2.1320 | 2.0835 | 2.0665 |
20.00 | 3.5040 | 3.4120 | 3.4580 | 3.4410 |
Precision
Intra-assay Precision | Inter-assay Precision | |||||
Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
22 | 22 | 22 | 6 | 6 | 6 | |
Average(ng/ml) | 0.42 | 2.09 | 6.22 | 0.51 | 2.10 | 6.03 |
Standard Deviation | 0.02 | 0.09 | 0.48 | 0.02 | 0.10 | 0.37 |
Coefficient of Variation(%) | 4.9 | 4.5 | 7.7 | 4.3 | 4.7 | 6.1 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human OPN into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 83% to 117% with an overall mean recovery of 108%.
Sample Values
Sample Matrix | Sample Evaluated | Range (ng/ml) | Detectable (%) | Mean of Detectable (ng/ml) |
---|---|---|---|---|
Serum | 30 | 1.1-6.74 | 100 | 3.97 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of OPN in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: OPN
Osteopontin (OPN), also known as bone sialoprotein (BSP), is a secreted SIBLING family protein that can be variably modified by O- and N-glycosylation, sulfation, phosphorylation, and transglutamination. OPN is widely expressed and is prominent in mineralized tissues. It inhibits bone mineralization and kidney stone formation and promotes inflammation, cell ad¬hesion, and migration. Its expression is upregulat¬ed during inflammation, obesity, atherosclerosis, cancer, and tissue damage and contributes to the pathophysiology of these conditions. The central region of OPN contains RGD and non-RGD binding sites for multiple integrins. Adjacent to the RGD motif is the sequence SLAYGLR (SVVYGLR in human) which serves as a cryptic binding site for additional integrins: it is masked in full length OPN but is exposed following OPN cleavage by multiple proteases in tumors and sites of tissue injury.